206 related articles for article (PubMed ID: 27146000)
1. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.
Pitisuttithum P; Islam D; Chamnanchanunt S; Ruamsap N; Khantapura P; Kaewkungwal J; Kittitrakul C; Luvira V; Dhitavat J; Venkatesan MM; Mason CJ; Bodhidatta L
Clin Vaccine Immunol; 2016 Jul; 23(7):564-75. PubMed ID: 27146000
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of WRSS1, a
Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
[No Abstract] [Full Text] [Related]
3. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.
Kotloff KL; Taylor DN; Sztein MB; Wasserman SS; Losonsky GA; Nataro JP; Venkatesan M; Hartman A; Picking WD; Katz DE; Campbell JD; Levine MM; Hale TL
Infect Immun; 2002 Apr; 70(4):2016-21. PubMed ID: 11895966
[TBL] [Abstract][Full Text] [Related]
5. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
[TBL] [Abstract][Full Text] [Related]
6. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH
Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694
[TBL] [Abstract][Full Text] [Related]
7. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
[TBL] [Abstract][Full Text] [Related]
8. Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children.
Sarker P; Mily A; Ara A; Haque F; Maier N; Wierzba TF; Walker RI; Venkatesan MM; Raqib R
J Infect Dis; 2021 Dec; 224(12 Suppl 2):S829-S839. PubMed ID: 34374425
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a Shigella sonnei human challenge model in Thailand.
Bodhidatta L; Pitisuttithum P; Chamnanchanant S; Chang KT; Islam D; Bussaratid V; Venkatesan MM; Hale TL; Mason CJ
Vaccine; 2012 Nov; 30(49):7040-5. PubMed ID: 23069701
[TBL] [Abstract][Full Text] [Related]
10. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.
Frenck RW; Baqar S; Alexander W; Dickey M; McNeal M; El-Khorazaty J; Baughman H; Hoeper A; Barnoy S; Suvarnapunya AE; Kaminski RW; Venkatesan MM
Vaccine; 2018 Aug; 36(32 Pt B):4880-4889. PubMed ID: 30037478
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
[TBL] [Abstract][Full Text] [Related]
12. Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever.
Wu Y; Chakravarty S; Li M; Wai TT; Hoffman SL; Sim BK
J Infect Dis; 2017 Jan; 215(2):259-268. PubMed ID: 27803169
[TBL] [Abstract][Full Text] [Related]
13. Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome.
Behar A; Fookes MC; Goren S; Thomson NR; Cohen D
Vaccine; 2015 Jun; 33(26):2978-83. PubMed ID: 25936664
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
Chakraborty S; Harro C; DeNearing B; Bream J; Bauers N; Dally L; Flores J; Van de Verg L; Sack DA; Walker R
Clin Vaccine Immunol; 2016 Apr; 23(4):315-25. PubMed ID: 26865592
[TBL] [Abstract][Full Text] [Related]
16. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.
Herrington DA; Van de Verg L; Formal SB; Hale TL; Tall BD; Cryz SJ; Tramont EC; Levine MM
Vaccine; 1990 Aug; 8(4):353-7. PubMed ID: 2204243
[TBL] [Abstract][Full Text] [Related]
17. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
[TBL] [Abstract][Full Text] [Related]
18.
Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
[No Abstract] [Full Text] [Related]
19. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
[TBL] [Abstract][Full Text] [Related]
20. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
